Apogee Therapeutics Advances APG777 in Key Phase 2 Trial

The latest update is out from Apogee Therapeutics ( (APGE) ).

On February 3, 2025, Apogee Therapeutics announced the dosing of the first patient in the Part B portion of their Phase 2 APEX clinical trial for APG777, targeting patients with moderate-to-severe atopic dermatitis. The trial combines Phase 2a and 2b protocols, with Part A seeing an exceeded enrollment of 123 patients, and Part B involving approximately 280 patients. This advancement underscores APG777’s potential in providing effective treatment options with reduced injection burdens and improved disease control, positioning Apogee as a competitive player in the I&I markets.

More about Apogee Therapeutics

Apogee Therapeutics is a clinical-stage biotechnology company focusing on novel biologics aimed at addressing inflammatory and immunology (I&I) markets, such as atopic dermatitis (AD), asthma, COPD, and eosinophilic esophagitis (EoE). Their antibody programs aim to surpass existing therapies by targeting established mechanisms, optimizing half-life, and enhancing efficacy.

YTD Price Performance: -12.28%

Average Trading Volume: 519,385

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $2.42B

For an in-depth examination of APGE stock, go to TipRanks’ Stock Analysis page.